News
-
Ampio Advances NCE001 Cancer Drug Into Preclinical Development Following Successful Recent Financing And The Granting Of Patents In USA, Canada, Europe And China
7/16/2012
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs (Ampion™, Optina™, Zertane™ & Zertane-ED™) announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.
-
Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
7/11/2012
Eli Lilly and Company (NYSE: LLY) announced today negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering an acute exacerbation of schizophrenia.
-
Titan Completes Preclinical Study Of A Continuous, Dopamine Agonist Treatment for Parkinson's Disease
7/10/2012
Titan Pharmaceuticals, Inc. (
OTCBB : TTNP) today announced that it has successfully completed investigation into the feasibility of a long-term, round-the-clock, non-fluctuating dopamine agonist treatment for Parkinson's disease. The preclinical study was primarily funded by a $495,000 grant awarded to Titan by the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program, and administered by the National Institute of Neurological Disorders and Stroke (NINDS). -
Patient-Derived Stem Cells Could Improve Drug Research For Parkinson's
7/4/2012
Researchers have taken a step toward personalized medicine for Parkinson's disease, by investigating signs of the disease in patient-derived cells and testing how the cells respond to drug treatments. The study was funded by the National Institutes of Health.
-
Ampio Contracts with Syngene to Manufacture Zertane-ED(TM), its Recently Patented Combination Drug to Treat both Premature Ejaculation (PE) and Erectile Dysfunction (ED)
7/2/2012
Ampio Pharmaceuticals, Inc. /quotes/zigman/5133505/quotes/nls/ampe AMPE +9.84% , a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) & Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane(TM) to treat PE in the USA.
-
Mayo Clinic Uses New Approach To Reverse Multiple Sclerosis In Mice Models
6/28/2012
Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.
- Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial 6/19/2012
-
Abbott Presents Results Of Clinical Studies Evaluating Its Investigational Treatment For Advanced Parkinson's Disease
6/18/2012
Today Abbott (NYSE: ABT) announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease. The abstracts include the results from the second interim analysis of a long-term safety and tolerability trial, as well as secondary endpoint analyses from the Phase 3 pivotal trial.
-
Lundbeck's Innovative Alzheimer's Drug Met Primary Cognition Endpoint
6/13/2012
Lundbeck Canada announced that its investigational Alzheimer's drug Lu AE58054 met its primary cognition endpoint in patients with Alzheimer's disease. This compound is a novel, selective 5-HT6receptor antagonist with a different mechanism of action than currently available Alzheimer's medications.
-
Diabetes Drug Could Be A Promising Therapy For Traumatic Brain Injury
5/29/2012
Although the death toll is relatively low for people who suffer from traumatic brain injury (TBI), it can have severe, life-long consequences for brain function.